A puppy-derived non-lactolytic streptococcal strain SA1 and its application
By screening and identifying puppy-derived non-lactolytic streptococci SA1, the shortcomings of pet probiotic products in regulating intestinal health have been addressed. A new strain with strong adhesion ability and acid and bile salt resistance has been provided for use in pet food and health products to improve pet intestinal health and immunity.
Patent Information
- Application Number
- CN202611509685.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-28
- Publication Date
- 2026-11-17
Smart Images

Figure CN123107879A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of microbial technology, specifically to a puppy-derived non-lactolytic streptococcus SA1 and its applications. Background Technology
[0002] As my country's pet economy enters a stage of high-quality development, the urban pet ownership rate has been rising year by year. The number of pets in the two core pet categories, cats and dogs, has exceeded 120 million, forming a huge market worth over 500 billion yuan. Consumers' emotional attachment to their pets is deepening, and their pet ownership philosophy is shifting from "basic needs" to "health and refinement." Precise nutritional intervention has become a core requirement for pet health management, with gut health, as a crucial cornerstone of pet metabolism and immune function, receiving widespread attention. The gut microbiota, as a complex micro-ecosystem within a pet, directly affects the efficiency of nutrient digestion and absorption, the integrity of the intestinal mucosal barrier, and the activity of immune cells. Once the gut microbiota is imbalanced, it can easily lead to various health problems such as diarrhea, constipation, indigestion, and allergies. In severe cases, it can also induce chronic inflammation and immune disorders, reducing the pet's quality of life.
[0003] Probiotics, as key functional components for regulating the gut microbiota, have become a core sector in the pet health food and supplement industry due to their advantages of being non-toxic and having targeted regulatory effects. By colonizing the pet's gut, they synergistically interact with the host's gut microbiota, promoting the proliferation of beneficial bacteria and optimizing the microbiota structure. Simultaneously, by producing metabolites such as lactic acid and acetic acid, they lower the intestinal pH, inhibiting the growth and colonization of pathogenic bacteria such as Escherichia coli and Salmonella. Furthermore, they enhance the expression of tight junction proteins in the intestinal mucosa, strengthening the intestinal barrier function, thereby improving the pet's digestive and absorptive efficiency, reducing intestinal discomfort symptoms, and enhancing the body's immunity.
[0004] Currently, probiotics are widely used in pet staple food, snacks, health products and prescription foods, and market demand continues to surge. However, in terms of technology application and product implementation, existing solutions still have significant room for optimization and are difficult to fully meet the precise health needs of pets. Summary of the Invention
[0005] The purpose of this invention is to provide a puppy-derived non-lactolytic streptococcus SA1 strain and its application. This strain is a strain with excellent probiotic properties selected after being isolated, screened and identified from the feces of healthy puppies, providing a new candidate strain for pet food and health care products.
[0006] The technical solution of this invention is: a puppy-derived non-lactolytic streptococcus SA1, wherein the non-lactolytic streptococcus SA1 has the accession number CGMCC NO.37097, is deposited at the China General Microbiological Culture Collection Center, the deposit date is December 16, 2025, the deposit address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, China, and is classified and named as non-lactolytic streptococcus Enterococcus foecalis.
[0007] Furthermore, the 16S rRNA gene sequence of the non-lactolytic streptococcus is shown in SEQ ID NO: 01.
[0008] Furthermore, the non-lactose-degrading Streptococcus SA1 possesses one or more of the following biological characteristics: inhibitory effects on Gram-positive and Gram-negative bacteria, including Escherichia coli, Staphylococcus aureus, Salmonella, methicillin-resistant Staphylococcus aureus, and Klebsiella pneumoniae; non-hemolytic; sensitive to ampicillin, penicillin, chloramphenicol, and cefazolin, and resistant to gentamicin, ciprofloxacin, and norfloxacin; acid resistance, bile salt resistance, and intestinal adhesion ability; and antioxidant properties.
[0009] The present invention also provides a puppy-derived non-lactolytic streptococcus SA1 or its metabolites.
[0010] Furthermore, its dosage forms include lyophilized powders, tablets, capsules, granules, powders, emulsions, and solutions.
[0011] Furthermore, this includes pet food or pet health products.
[0012] Furthermore, the pet food includes pet yogurt, pet milk powder, pet cheese, pet snacks, pet staple food, or pet wet food.
[0013] Furthermore, the pets include canines.
[0014] Compared with the prior art, the present invention has the following beneficial effects:
[0015] 1. This invention provides a novel juvenile non-lactolytic streptococcus SA1 strain with strong adhesion ability and good probiotic capacity.
[0016] 2. The puppy-derived non-lactolytic streptococcus SA1 provided by this invention is non-hemolytic and has high biosafety.
[0017] 3. The puppy-derived non-lactolytic streptococcus SA1 provided by this invention has good acid resistance and bile salt resistance.
[0018] 4. The puppy-derived non-lactolytic streptococcus SA1 provided by this invention is a strain with excellent probiotic properties selected after isolation, screening and identification from puppy feces. It has a good inhibitory effect on common pathogenic bacteria and is sensitive to a variety of antibiotics. It provides a new candidate strain for pet food, health care products or probiotic preparations and has broad application prospects in the preparation of pet food, health care products and pharmaceuticals. Attached Figure Description
[0019] Figure 1 This is the result of the acid resistance test at pH=2.5 in Example 1.
[0020] Figure 2 This is the result of the bile salt tolerance test at a concentration of 0.3% in Example 1.
[0021] Figure 3 This is the result of the antibacterial ability of puppy-derived non-lactolytic streptococcus SA1 in Example 1.
[0022] Figure 4 This is the annotation result of the BLAST database in Example 2.
[0023] Figure 5 This is the colony morphology of puppy-derived non-lactolytic streptococci SA1 in Example 2.
[0024] Figure 6 This is the growth curve of puppy-derived non-lactolytic streptococcus SA1 in Example 3.
[0025] Figure 7 This is the result of the in vitro acid resistance of puppy-derived non-lactolytic streptococcus SA1 in Example 3.
[0026] Figure 8 This is the result of the in vitro bile salt tolerance of puppy-derived non-lactolytic streptococcus SA1 in Example 3.
[0027] Figure 9 This is the result of the hemolytic ability of puppy-derived non-lactolytic streptococci SA1 in Example 3.
[0028] Figure 10 This is the result of the adhesion experiment of puppy-derived non-lactolytic streptococcus SA1 in Example 3.
[0029] Figure 11 This is the result of the DPPH free radical scavenging test conducted by puppy-derived non-lactolytic streptococcus SA1 in Example 3.
[0030] Figure 12 This is the result of the test on ABTS free radical scavenging by puppy-derived non-lactolytic streptococcus SA1 in Example 3. Detailed Implementation
[0031] The following examples are provided to better understand the present invention, but do not limit the invention. Unless otherwise specified, the experimental methods in the following examples are conventional methods. Unless otherwise specified, the experimental materials used in the following examples were purchased from conventional biochemical reagent companies. The quantitative experiments in the following examples were all performed in triplicate, and the results were averaged.
[0032] Example 1: Screening and isolation of Streptococcus alactolyticus SA1 from puppies
[0033] 1. Cultivation and isolation of bacterial strains;
[0034] Fresh, healthy puppy fecal samples were selected for strain screening. After serial dilution with sterile PBS buffer (purchased from Beijing Saive Biotechnology Co., Ltd.), the samples were spread onto MRS solid medium containing 1% CaCO3 and incubated at 37°C for 48 h in an anaerobic incubator. Single colonies with a clear transparent zone (white or milky white) were picked, Gram-stained, and examined under a microscope. Rod-shaped, Gram-positive strains were selected. From these strains, the best-growing non-lactolytic streptococcal strains SA1, SA2, SA3, and SA4 were selected and enriched in an anaerobic incubator at 37°C. The bacterial cells were then mixed with sterile 50% glycerol and stored at -80°C for later use.
[0035] 2. Screening of strains
[0036] The SA1, SA2, SA3, and SA4 strains were inoculated into MRS broth medium under aseptic conditions after being preserved in glycerol. The cultures were then anaerobic at 37°C for 24 h and activated for three generations. After centrifugation, the culture medium was washed 2-3 times with sterile PBS.
[0037] The acid resistance, bile salt resistance, and antibacterial properties of the above-mentioned SA1, SA2, SA3, and SA4 strains were tested.
[0038] The specific test procedures for acid resistance, bile salt resistance, and adhesion are as follows:
[0039] (1) Acid resistance test
[0040] The washed culture medium was resuspended in MRS broth medium at pH 2.5 and anaerobically cultured at 37°C. Samples were taken at 0 h and 3 h for serial dilution and spread on MRS solid medium plates. After anaerobic culture at 37°C for 48 h, the samples were counted.
[0041] Strain survival rate (%) = (N1 / N0) * 100%;
[0042] Where N0 is the number of viable bacteria (CFU / mL) at 0 h; N1 is the number of viable bacteria (CFU / mL) after the strain has been acid-resistant for 3 h.
[0043] Experimental results are as follows Figure 1 As shown, strain SA1 had the highest survival rate, reaching 99.11%.
[0044] CFU (colony forming unit): The total number of bacterial communities per unit volume; in viable cell culture counting, a colony formed by the growth and reproduction of a single cell or multiple cells aggregated on a solid culture medium is called a colony forming unit, which expresses the number of viable bacteria.
[0045] (2) Bile salt tolerance test
[0046] The washed culture medium was resuspended in MRS broth medium containing 0.3% bile salts and cultured anaerobically at 37°C. Samples were taken at 0 h and 3 h for serial dilution and spread on MRS solid medium plates. After anaerobic culture at 37°C for 48 h, the samples were counted.
[0047] Strain survival rate (%) = (N1 / N0) * 100%,
[0048] Where N0 is the number of viable bacteria (CFU / mL) at 0h; N1 is the number of viable bacteria (CFU / mL) of the strain after 3h of bile salt tolerance.
[0049] Experimental results are as follows Figure 2 As shown, the survival rate of strain SA1 was 87.50%.
[0050] (3) Determination of the antibacterial activity of puppy-derived non-lactolytic streptococci SA1
[0051] Pet food contains a large amount of nutrients, but in daily life, food spoilage and deterioration occur, harming pets' health and causing economic losses. Microbial contamination and growth are the main causes of food spoilage; therefore, the antibacterial properties of SA1 are one of the safety indicators for its application in food.
[0052] Five common foodborne pathogens—Escherichia coli, Staphylococcus aureus, Salmonella, methicillin-resistant Staphylococcus aureus, and Klebsiella pneumoniae—were used as indicator bacteria. After activating the indicator bacteria for three generations, the Oxford cup method was used to preliminarily determine their antibacterial activity.
[0053] The Oxford cup method was used, specifically as follows: Activated bacterial strains were inoculated into MRS broth at a 2% (v / v) inoculum and anaerobically cultured at 37°C for 24 h. Activated *Escherichia coli*, *Staphylococcus aureus*, and *Salmonella* bacterial suspensions were serially diluted 10-fold, with the 10-fold dilution selected as the final dilution. 2Set aside the bacterial culture. Add 5 mL of LB agar medium to the petri dish for sealing. After cooling and solidification, place Oxford cups evenly in the dish. Take 100 μL of each gradient indicator bacterial culture and add it to 15 mL of LB agar at 50-60℃. Mix well and slowly pour into the plate containing the Oxford cups. After cooling and solidification, remove the Oxford cups with tweezers to form 8×6×10 round holes.
[0054] Add 200 μL of the bacterial fermentation supernatant to each well, diffuse at 4°C for 12 h, and then anaerobic incubate at 37°C for 9–12 h. Observe for the formation of inhibition zones and measure their diameter using calipers. Each experiment was repeated three times, and the results are expressed as x ± s.
[0055] Experimental results are as follows Figure 3 As shown, bacteria SA1 exhibits strong inhibitory effects against both Gram-positive bacteria (Staphylococcus aureus, methicillin-resistant Staphylococcus aureus) and Gram-negative bacteria (Escherichia coli, Salmonella, Klebsiella pneumoniae), with inhibition zone diameters exceeding 17.5 mm. The strongest inhibitory effect was observed against Staphylococcus aureus, with an inhibition zone diameter of 21.5 mm in the supernatant.
[0056] Depend on Figure 1 , Figure 2 and Figure 3 The results showed that the puppy-derived non-lactolytic streptococcus SA1 had extremely strong antibacterial ability, with an inhibition zone of up to 21.5 mm, which was much higher than that of other puppy-derived non-lactolytic streptococci. Furthermore, after surviving for 3 hours under acid-resistant conditions at pH 2.5 and bile-resistant conditions at a bile salt concentration of 0.3%, its survival rate reached 99.11% and 87.50%, respectively, demonstrating good acid and bile salt resistance.
[0057] Example 2: Identification of Puppy-Derived Non-Lactosolytic Streptococcus SA1
[0058] After extracting genomic DNA from the selected strain SA1, the 16S rRNA gene was amplified using primers 27F / 1492R. The PCR product of the 16S rRNA gene was then purified by gel extraction and sent for sequencing. The sequencing results were then compared with the NCBI database using BLAST. The sequenced sequence is shown below:
[0059]
[0060] The sequencing results were used to perform a homology search in the gene database on the NCBI website using BLAST. The results showed the highest similarity to *Streptococcus non-lactolyticus*. Figure 4 As shown, 99.93% of the genes conform to the genus *Streptococcus non-lactolyticus*.
[0061] The strain SA1 was diluted and spread, and the colony morphology was observed. The results are as follows: Figure 5 As shown, based on the morphological characteristics of SA1 colonies, strain SA1 was identified as non-lactose-degrading streptococcus.
[0062] Example 3: Determination of the probiotic properties of puppy-derived non-lactolytic streptococcus SA1
[0063] 1. Growth curve determination of non-lactolytic streptococcal SA1 from puppies
[0064] The cultured SA1 bacterial suspension was activated for three generations and inoculated into MRS broth medium. It was then placed in an incubator at 37°C for anaerobic culture. The viable count of each bacterium was measured at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 h.
[0065] Growth curves of *Streptococcus non-lactolyticus* SA1 from puppies were plotted. Results are shown in [Table missing]. Figure 6 As shown.
[0066] 2. In vitro acid and bile salt tolerance test of non-lactolytic streptococcal SA1 from puppies
[0067] The cultured SA1 bacterial suspension was activated for three generations and inoculated into MRS broth medium with pH 1.5, 2 and bile salt concentrations of 0.1% and 0.2%, respectively. The medium was placed in an incubator at 37°C for anaerobic culture, and samples were taken at 0 h and 3 h for plate counting.
[0068] The experimental results are shown below. Figure 7 and Figure 8 ;Depend on Figure 7 It can be seen that when this bacterium is cultured in an environment with pH 1.5 and pH 2 for 0-3 hours, the bacterial cells grow stably, and the viable cell count is consistently above 10. 8 It has a concentration of CFU / mL or higher and strong acid resistance.
[0069] Depend on Figure 8 It can be seen that the bacteria grows relatively stably in a medium with a bile salt concentration of 0.1%; after culturing in a medium with a bile salt concentration of 0.2% for 3 hours, the survival rate is 95.40%, indicating strong bile salt tolerance.
[0070] 3. Antibiotic susceptibility testing of non-lactolytic streptococcal SA1 from puppies
[0071] The overuse of antibiotics in the pharmaceutical industry can lead to increased drug resistance in pathogenic strains, and the gut microbiota in humans is prone to disorder and imbalance. Therefore, obtaining antibiotic-sensitive lactic acid bacteria has become one of the important indicators of whether their application in food is safe.
[0072] The concentration of the fermentation broth for each strain after 24 h of culture was adjusted to 10. 8 CFU / mL, add 100 μL of bacterial suspension to an MRS solid plate and spread it evenly, then let it dry. Place an average of 5-6 drug sensitivity discs in each plate. After diffusion at 4℃ for 12 hours, anaerobic culture at 37℃ for 9-12 hours. Refer to the drug sensitivity disc instructions to determine the sensitivity of the strain to the drug.
[0073] The results are shown in Table 1. Non-lactolytic streptococci SA1 were extremely sensitive to ampicillin, penicillin, chloramphenicol, and cefazolin (cephalosporins), but resistant to gentamicin, ciprofloxacin, and norfloxacin.
[0074] Table 1 Antibiotic susceptibility testing
[0075]
[0076] S: Susceptible; I: Intermediate; R: Tolerable
[0077] 4. Determination of hemolytic ability of non-lactolytic streptococcal SA1 from puppies
[0078] Use an inoculation loop to streak a small amount of bacterial suspension onto a Columbia blood agar plate. Incubate anaerobically at 37°C for 24-36 hours and observe for the presence or absence of hemolysis zones. Based on the hemolysis phenomenon, it can be classified into α-hemolysis (greenish-yellow hemolysis), β-hemolysis (completely transparent hemolysis zone), and γ-hemolysis (no hemolysis).
[0079] The hemolysis test can assess the safety of a bacterial strain by detecting whether it exhibits hemolytic activity. The results are as follows: Figure 9 As shown, this strain did not exhibit hemolysis on blood agar plates, indicating γ-hemolysis. Using Staphylococcus aureus as a positive control, a completely transparent hemolytic zone was observed around the Staphylococcus aureus, indicating β-hemolysis. These results demonstrate that this non-lactose-lysing streptococcal strain is non-hemolytic and a safe, non-toxic strain.
[0080] 5. Adhesion test
[0081] After resuscitation, Caco-2 cells (human colon cancer cells) were seeded into cell culture flasks and fresh DMEM complete medium (DMEM high-glucose medium containing double antibiotics purchased from Beijing Solarbio Science & Technology Co., Ltd., 20% fetal bovine serum) were added. The cells were cultured in an incubator at 37°C and 5% CO2, with the cell culture medium changed every two days. When the cells reached a confluence of approximately 70%-80%, they were passaged using a 0.25% trypsin-EDTA digestion solution (purchased from Beijing Solarbio Science & Technology Co., Ltd.). The final culture medium used was DMEM incomplete medium.
[0082] FITC solution preparation: FITC (fluorescein isothiocyanate) labeling solution (purchased from Beijing Solarbio Science & Technology Co., Ltd.): Before preparation, place FITC stored at 4℃ at room temperature for 30 min, accurately weigh 0.5 g and dissolve it in 1 mL of dimethyl sulfoxide (DMSO) to prepare a 500 mg / mL solution, and dilute it 1000 times (add 10 μL to a 9.99 mL DMSO brown 15 mL EP tube) to obtain a working concentration of 500 μg / mL labeling solution, and store it at 4℃.
[0083] Fluorescent labeling: 1 mL of freshly cultured probiotic suspension was centrifuged in a brown 1.5 mL EP tube (4℃, 4000 rpm, 5 min). The suspension was washed three times with sterile PBS. After the last wash, the bacterial cells were resuspended in 1 mL of FITC solution that had been incubated at room temperature for 30 min beforehand. The suspension was then incubated in the dark at 37℃ with shaking for 2 h. After the dark incubation, the suspension was centrifuged (4℃, 4000 rpm, 5 min) and washed three times with sterile PBS to remove unbound FITC labeling solution. The suspension was then resuspended in 1 mL of DMEM cell culture medium. 200 μL of the suspension was added to a black 96-well plate, and the relative fluorescence intensity (RFU) of the strain at wavelengths of 485 nm (absorption wavelength) and 530 nm (emission wavelength) was measured. This RFU value was recorded as the relative fluorescence intensity value R0 of the strain before adhesion.
[0084] Adhesion test: Caco-2 cells were passaged for more than 3 generations to prepare for the test.
[0085] Before the experiment, the cell concentration was adjusted to 5 × 10⁻⁶ cells using cell culture medium. 5Cells were cultured at a density of 1 mL / well in 24-well cell culture plates. After the cells reached a monolayer (approximately 24 hours), the culture medium was discarded. The cells were washed three times with sterile PBS, and 0.6 mL of labeled probiotic suspension was added. Each bacterial strain was used in three replicate wells. The cells were incubated in the dark at 37°C and 5% CO2 for 2 hours. After incubation, the culture medium was discarded, and the cells were washed three times with sterile PBS to remove any strains that had not adhered to the cells. 0.3 mL of trypsin was added to each well to digest the cells for 5 minutes, and digestion was terminated with DMEM cell culture medium. The relative fluorescence intensity (RFU) of the cell suspension was measured at the same wavelength and recorded as the relative fluorescence intensity R of the adhered strain.
[0086] Adhesion rate (%) calculation formula: R / R0 × 100%,
[0087] Where R represents the relative fluorescence intensity value of the strain after adhesion, obtained by incubating, washing and digesting probiotics with Caco-2 cells; R0 represents the relative fluorescence intensity value of the initial probiotic suspension (after labeling and before cell addition) measured under the same wavelength conditions.
[0088] The experimental results are shown in Figure 10 As shown, the adhesion rate of strain SA1 can reach 63.82%.
[0089] 6. DPPH free radical scavenging test
[0090] Bacterial cell collection and bacterial suspension concentration adjusted to 10 8 CFU / mL, using the DPPH free radical scavenging ability kit (purchased from Beijing Solarbio Science & Technology Co., Ltd.), and following the instructions in the manual.
[0091] DPPH free radical scavenging rate (%) = (1 - (A assay - A control) / A blank) × 100%,
[0092] Where A represents the absorbance of the blank group, which is usually a reaction system without the sample, only with DPPH working solution and solvent (such as anhydrous ethanol), reflecting the initial level of DPPH free radicals; A represents the absorbance of the sample group, which is the absorbance after the probiotic bacterial solution reacts with the DPPH working solution. At this time, DPPH is cleared by the antioxidants in the sample, and the absorbance will decrease; A represents the absorbance of the sample control group, which is the absorbance after the sample itself (bacterial solution) is mixed with the solvent (replacing DPPH). This step is to subtract the influence of the color or turbidity of the bacterial solution on the absorbance, and to avoid misjudging the absorbance value of the bacterial solution itself as the effect of free radical scavenging.
[0093] The experimental results are shown in Figure 11 The bacterial suspension of strain SA1 showed a DPPH free radical scavenging rate of 95.36%, indicating a certain degree of antioxidant activity.
[0094]
[0095] 7. ABTS free radical scavenging test
[0096] Bacterial cell collection and bacterial suspension concentration adjusted to 10 8 CFU / mL, using the ABTS Free Radical Scavenging Ability Kit (Beijing Solarbio Science & Technology Co., Ltd.), and following the instructions in the manual.
[0097] ABTS free radical scavenging rate (%) = (1 - (A assay - A control) / A blank) × 100%
[0098] The experimental results are shown in Figure 12 The supernatant of strain SA1 showed an ABTS free radical scavenging rate of 98.45%, indicating a certain degree of antioxidant activity.
[0099]
[0100] Finally, it should be noted that the above description of the present invention is merely a preferred embodiment and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A puppy-derived non-lactolytic streptococcus SA1, characterized in that, The non-lactolytic streptococcus SA1 has the accession number CGMCC NO.37097, is deposited at the China General Microbiological Culture Collection Center, on December 16, 2025, at Institute of Microbiology, Chinese Academy of Sciences, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, China.
2. The puppy-derived non-lactolytic streptococcus SA1 according to claim 1, characterized in that, The 16S rRNA gene sequence of the non-lactolytic streptococcus is shown in SEQ ID NO:
01.
3. The puppy-derived non-lactolytic streptococcus SA1 according to claim 2, characterized in that, The non-lactose-degrading Streptococcus SA1 possesses one or more of the following biological characteristics: it has inhibitory effects on Gram-positive and Gram-negative bacteria, including Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, methicillin-resistant Staphylococcus aureus, and Klebsiella pneumoniae; it is non-hemolytic. It is sensitive to ampicillin, penicillin, chloramphenicol, and cefazolin, and resistant to gentamicin, ciprofloxacin, and norfloxacin; it has acid resistance, bile salt resistance, and intestinal adhesion ability; and it has antioxidant properties.
4. A product, characterized in that: It contains the puppy-derived non-lactolytic streptococcus SA1 or its metabolites as described in claim 1.
5. The product according to claim 4, characterized in that: Its dosage forms include lyophilized powder, tablets, capsules, granules, powders, emulsions, and solutions.
6. The product according to claim 4, characterized in that: This includes pet food or pet health products.
7. A product according to claim 6, characterized in that: The pet food includes pet yogurt, pet milk powder, pet cheese, pet snacks, pet staple food, or pet wet food.
8. The product according to claim 6 or 7, characterized in that, The pets include canines.
